Celldex Therapeutics Total Liabilities 2010-2022 | CLDX

Celldex Therapeutics total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Celldex Therapeutics Annual Total Liabilities
(Millions of US $)
2021 $25
2020 $26
2019 $29
2018 $32
2017 $79
2016 $118
2015 $47
2014 $36
2013 $27
2012 $30
2011 $29
2010 $35
2009 $67
Celldex Therapeutics Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $26
2021-12-31 $25
2021-09-30 $23
2021-06-30 $22
2021-03-31 $25
2020-12-31 $26
2020-09-30 $26
2020-06-30 $23
2020-03-31 $29
2019-12-31 $29
2019-09-30 $30
2019-06-30 $33
2019-03-31 $35
2018-12-31 $32
2018-09-30 $40
2018-06-30 $50
2018-03-31 $57
2017-12-31 $79
2017-09-30 $100
2017-06-30 $115
2017-03-31 $112
2016-12-31 $118
2016-09-30 $35
2016-06-30 $36
2016-03-31 $42
2015-12-31 $47
2015-09-30 $34
2015-06-30 $37
2015-03-31 $32
2014-12-31 $36
2014-09-30 $32
2014-06-30 $32
2014-03-31 $27
2013-12-31 $27
2013-09-30 $24
2013-06-30 $19
2013-03-31 $29
2012-12-31 $30
2012-09-30 $29
2012-06-30 $28
2012-03-31 $29
2011-12-31 $29
2011-09-30 $28
2011-06-30 $26
2011-03-31 $27
2010-12-31 $35
2010-09-30 $60
2010-06-30 $62
2010-03-31 $64
2009-12-31 $67
2009-09-30 $50
2009-06-30 $50
2009-03-31 $52
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.061B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00